Literature DB >> 21296693

Adverse events following pandemic influenza vaccine Pandemrix® reported in the French military forces--2009-2010.

Aurélie Mayet1, Caroline Ligier, Kristel Gache, Ghislain Manet, Philippe Nivoix, Aissata Dia, Rachel Haus-Cheymol, Catherine Verret, Sandrine Duron, Nina Faure, Martine Piarroux, Frank De Laval, Fabrice Simon, Christophe Decam, Hervé Chaudet, Jean-Baptiste Meynard, Christophe Rapp, Xavier Deparis, René Migliani.   

Abstract

BACKGROUND: In the face of the A(H1N1) 2009 influenza pandemic, in October 2009 the French military health service (SSA) initiated a large vaccination campaign with Pandemrix(®) vaccine in the military forces. The aim of this study was to describe vaccine adverse events (VAE) reported during this campaign.
METHODS: VAE and the number of people vaccinated were surveyed by the SSA Epidemiological network across all military forces during the campaign, from October 2009 to April 2010. For each case, a notification form was completed, providing patient and clinical information. Three types of VAE were considered: non-serious, serious and unexpected.
RESULTS: There were 315.4 reported VAE per 100,000 vaccinations. Vaccination and VAE incidence rate peaks coincided with influenza epidemic peak in early December. The number of injected doses was 49,138, corresponding to a 14.5% vaccination coverage among military personnel, and 155 VAE were reported, including 5 serious VAE (1 Guillain-Barre syndrome, 2 malaises and 1 convulsive episode). Most VAE were non-serious (97.1%). Among these, 6 cases of local, rapidly regressive paresthesia were observed. DISCUSSION: The military VAE surveillance system constitutes the only observatory on benign VAE in France. The reporting rate was much higher after the pandemic vaccine than after the seasonal vaccine, which may be a reflection of stimulated reporting. This report provides a useful description of VAE among military personnel during a mass emergency vaccination program, showing that the tolerance of the pandemic vaccine appeared acceptable.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21296693     DOI: 10.1016/j.vaccine.2011.01.056

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

Review 1.  [Guillain-Barré syndrome after exposure to influenza].

Authors:  H-P Hartung; B Keller-Stanislawski; R A Hughes; H C Lehmann
Journal:  Nervenarzt       Date:  2012-06       Impact factor: 1.214

2.  The responses of Aboriginal Canadians to adjuvanted pandemic (H1N1) 2009 influenza vaccine.

Authors:  Ethan Rubinstein; Gerald Predy; Laura Sauvé; Greg W Hammond; Fred Aoki; Chris Sikora; Yan Li; Barbara Law; Scott Halperin; David Scheifele
Journal:  CMAJ       Date:  2011-07-25       Impact factor: 8.262

3.  Adverse events following pandemic influenza A (H1N1) 2009 monovalent and seasonal influenza vaccinations during the 2009-2010 season in the active component U.S. military and civilians aged 17-44years reported to the Vaccine Adverse Event Reporting System.

Authors:  Barbara H Bardenheier; Susan K Duderstadt; Renata J M Engler; Michael M McNeil
Journal:  Vaccine       Date:  2016-07-19       Impact factor: 3.641

4.  Risk of presentation to hospital with epileptic seizures after vaccination with monovalent AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine (Pandemrix): self controlled case series study.

Authors:  Lisen Arnheim-Dahlström; Jonas Hällgren; Caroline E Weibull; Pär Sparén
Journal:  BMJ       Date:  2012-12-18

5.  Short and long-term safety of the 2009 AS03-adjuvanted pandemic vaccine.

Authors:  Gaston De Serres; Marie-Claude Gariépy; Brenda Coleman; Isabelle Rouleau; Shelly McNeil; Mélanie Benoît; Allison McGeer; Ardith Ambrose; Judy Needham; Chantal Bergeron; Cynthia Grenier; Kenna Sleigh; Arlene Kallos; Manale Ouakki; Najwa Ouhoummane; Grant Stiver; Louis Valiquette; Anne McCarthy; Julie Bettinger
Journal:  PLoS One       Date:  2012-07-03       Impact factor: 3.240

Review 6.  Best vaccination practice and medically attended injection site events following deltoid intramuscular injection.

Authors:  Ian F Cook
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

7.  Population-Based Incidence of Guillain-Barré Syndrome During Mass Immunization With Viral Vaccines: A Pooled Analysis.

Authors:  Fengge Wang; Donglan Wang; Yingjie Wang; Cancan Li; Yulu Zheng; Zheng Guo; Pengcheng Liu; Yichun Zhang; Wei Wang; Youxin Wang; Haifeng Hou
Journal:  Front Immunol       Date:  2022-02-03       Impact factor: 7.561

8.  Localized lipoatrophy and inadvertent subcutaneous administration of a COVID-19 vaccine.

Authors:  Ian F Cook
Journal:  Hum Vaccin Immunother       Date:  2022-03-08       Impact factor: 4.526

9.  Acute disseminated encephalomyelitis onset: evaluation based on vaccine adverse events reporting systems.

Authors:  Paolo Pellegrino; Carla Carnovale; Valentina Perrone; Marco Pozzi; Stefania Antoniazzi; Emilio Clementi; Sonia Radice
Journal:  PLoS One       Date:  2013-10-16       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.